Document is current
Any future updates will be listed below
-
Authors
Yanada, Masamitsu https://orcid.org/0000-0003-1602-9775
Yamamoto, Kazuhito
- License Information
-
More Information
Article History
Received: 28 November 2021
Revised: 19 January 2022
Accepted: 19 January 2022
First Online: 29 January 2022
Declarations
:
: MY received research funding from AbbVie, AstraZeneca, Celgene, Chugai, Eisai, IQVIA/Genmab, IQVIA/Incyte, Mundipharma, Nippon Shinyaku, Novartis, Ono Pharmaceutical, Otsuka Pharmaceutical, Solasia Pharma, SymBio, Takeda, Yakult, and Zenyaku. KY received research funding from AbbVie, AstraZeneca, Celgene, Chugai, Eisai, HUYA/IQVIA Services Japan, IQVIA/Genmab, IQVIA/Incyte, Meiji Seika Pharma, Micron, Mundipharma, Nippon Shinyaku, Novartis, Ono Pharmaceutical, Otsuka Pharmaceutical, Solasia Pharma, SymBio, Takeda, Yakult, and Zenyaku; consulting fees from Meiji Seika Pharma; and honoraria from AbbVie, ADC Therapeutics, AstraZeneca, Bristol-Myers Squibb, Celgene, Chugai, Daiichi Sankyo, Eisai, HUYA/IQVIA Services Japan, Janssen, Kyowa Kirin, Meiji Seika Pharma, MSD, Nippon Shinyaku, Novartis, Ono Pharmaceutical, Otsuka Pharmaceutical, Sanofi, Stemline Therapeutics, SymBio, Takeda, Yakult, and Zenyaku.
